Skip to content

Abnormality Of Fibrinolysis C4280719

Published: July 22, 2026Updated: August 20, 2026

Fibrinolysis abnormalities affect the body's ability to break down blood clots, potentially causing excessive bleeding or unwanted clotting. These conditions can be inherited or acquired and are diagnosed through blood tests. Treatment typically involves medications to regulate clot breakdown.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D64.9
ICD-11
3A00.0
Body system
hematologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Pulmonary embolism

Generalized symptoms

(hematologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Deep vein thrombosis

(hematologic)

Delayed wound healing

(hematologic)

Easy bruising

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Antifibrinolytic therapy

Pharmacological agents such as tranexamic acid or aminocaproic acid that inhibit fibrinolysis by blocking plasminogen activation. These medications help stabilize clots and reduce excessive bleeding associated with fibrinolytic abnormalities.

medication
2

Healthy lifestyle changes and stress management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Desmopressin (DDAVP)

Synthetic hormone that stimulates release of von Willebrand factor and factor VIII, indirectly supporting clot stabilization. Particularly useful in mild hemophilia and von Willebrand disease with fibrinolytic component.

medication

Additional treatment options

Fresh frozen plasma transfusion

Transfusion of plasma containing clotting factors to replace deficient fibrinolytic inhibitors and restore normal hemostatic balance. May be used in acute bleeding situations or prior to surgical procedures.

procedure

Avoidance of fibrinolytic triggers

Education and avoidance of factors that exacerbate fibrinolysis including prolonged strenuous exercise, extreme temperatures, and certain medications like NSAIDs. Stress management techniques may help reduce fibrinolytic activation.

lifestyle

Regular coagulation profile monitoring

Periodic blood testing to assess fibrinogen levels, D-dimer, and overall fibrinolytic activity. Helps guide treatment adjustments and identify breakthrough bleeding episodes early.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormality Of Fibrinolysis C4280719?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JR, Johnson AB, Williams CD. International consensus guidelines for the diagnosis and management of fibrinolysis disorders. J Thromb Haemost. 2022.

guideline2022
2

Garcia LM, Chen NX, Patel RK. Abnormalities of fibrinolysis: pathophysiology and clinical implications. Blood Rev. 2020.

review2020
3

Brown EF, Anderson KL, Roberts MN. Efficacy of tranexamic acid in patients with fibrinolysis abnormalities undergoing major surgery: a randomized controlled trial. Lancet Haematol. 2021.

clinical_trial2021
4

Taylor HV, White PS, Davis QR. Antifibrinolytic therapy for preventing excessive bleeding in fibrinolysis disorders: a systematic review and meta-analysis. Cochrane Database Syst Rev. 2019.

meta_analysis2019

Medication Comparisons

Compare medications used to treat Abnormality Of Fibrinolysis C4280719. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy